c-Met expression in renal cell carcinoma with bone metastases

Paiva, R.; Gomes, Inês Afonso; Casimiro, Sandra; Fernandes, Isabel; Costa, Luís

doi:10.1016/j.jbo.2020.100315

Cited by 14 publications

(8 citation statements)

References 101 publications

(127 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…142 RTKs play a crucial role in maintaining the characteristics of CSCs, such as self-renewal capacity, viability, invasiveness, and tumorigenicity. Several RTKs have been identified to be involved in CSC maintenance, including Eph receptor, 143 MET, 144 EGFR, 145 and others. Taking MET as an example, it is primarily expressed in stem and progenitor cells in normal tissues, while its expression is absent in cells that possess the ability to differentiate.…”

Section: Rtks As Stem Cell Markersmentioning

confidence: 99%

Receptor tyrosine kinases: biological functions and anticancer targeted therapy

Zhang,

2023

MedComm

View full text Add to dashboard Cite

Receptor tyrosine kinases (RTKs) are a class of protein kinases that play crucial roles in various cellular processes, including cell migration, morphological differentiation, cell growth, and angiogenesis. In humans, 58 RTKs have been identified and categorized into 20 distinct families based on the composition of their extracellular regions. RTKs are primarily activated by specific ligands that bind to their extracellular region. They not only regulate tumor transformation, proliferation, metastasis, drug resistance, and angiogenesis, but also initiate and maintain the self‐renewal and cloning ability of cancer stem cells. Accurate diagnosis and grading of tumors with dysregulated RTKs are essential in clinical practice. There is a growing body of evidence supporting the benefits of RTKs‐targeted therapies for cancer patients, and researchers are actively exploring new targets and developing targeted agents. However, further optimization of RTK inhibitors is necessary to effectively target the diverse RTK alterations observed in human cancers. This review provides insights into the classification, structure, activation mechanisms, and expression of RTKs in tumors. It also highlights the research advances in RTKs targeted anticancer therapy and emphasizes their significance in optimizing cancer diagnosis and treatment strategies.

show abstract

Section: Rtks As Stem Cell Markersmentioning

confidence: 99%

Receptor tyrosine kinases: biological functions and anticancer targeted therapy

Zhang,

2023

MedComm

View full text Add to dashboard Cite

show abstract

“… 97 MET is a proto-oncogene encoding c-Met, and the activation of c-Met promotes the development of tumor cells, which is an important mechanism for cancer development. 98 Angiopoietin/Tie-2 signaling promotes the blood vessels within the tumor tissue, and Tie-2 is specifically expressed in endothelial cells. 99 Angiopoietin/Tie2 and MET pathways promote tumor angiogenesis, metastasis, and macrophage infiltration.…”

Section: Combined Treatmentmentioning

confidence: 99%

Research Progress of Tumor Microenvironment Targeted Therapy for Clear Cell Renal Cell Carcinoma

2023

View full text Add to dashboard Cite

Renal clear cell carcinoma (ccRCC) and the tumor microenvironment (TME) influence each other, leading to the tumor microenvironment that can guide the corresponding treatment. With the deepening of research, some treatment options have achieved good results, such as tyrosine kinase inhibitors, immune checkpoint inhibitors, and so on. As the link between TME and malignancy is constantly discovered, more targeted studies on different components of TME are increasing, and this targeted therapy is a new method for treating ccRCC, and also a current research hotspot. This review summarizes the characteristics of the ccRCC tumor microenvironment, the outcomes of different treatments, and some potential targets.

show abstract

“…77 A known hypoxia-inducible factor (HIF-1) downstream target, c-Met, is activated by hepatocyte growth factor binding and induces tumorigenesis via mitogenactivated protein kinase, PI3K, and signal transducer and activator of transcription 3 (STAT3) signaling. 78,79 It is also involved in immune microenvironment modulation through the recruitment of neutrophils, driving an inflammatory immunosuppressive environment and inducing PD-L1 expression. 78,79 Cabozantinib, a multitargeted TKI with activity against c-Met, is approved for the treatment of mRCC, both as a single agent and in combination with nivolumab.…”

Section: Systemic Therapy Biologic Insights and Implications For Therapymentioning

confidence: 99%

“…78,79 It is also involved in immune microenvironment modulation through the recruitment of neutrophils, driving an inflammatory immunosuppressive environment and inducing PD-L1 expression. 78,79 Cabozantinib, a multitargeted TKI with activity against c-Met, is approved for the treatment of mRCC, both as a single agent and in combination with nivolumab. 7,80,81 The CABRAMET phase 2 study is currently evaluating the efficacy of cabozantinib in mRCC BM (Clini calTr ials.gov identifier NCT03967522).…”

Section: Systemic Therapy Biologic Insights and Implications For Therapymentioning

confidence: 99%

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Hasanov

Yeboa

Tucker

et al. 2022

CA A Cancer J Clinicians

View full text Add to dashboard Cite

Brain metastases are a challenging manifestation of renal cell carcinoma. We have a limited understanding of brain metastasis tumor and immune biology, drivers of resistance to systemic treatment, and their overall poor prognosis. Current data support a multimodal treatment strategy with radiation treatment and/or surgery. Nonetheless, the optimal approach for the management of brain metastases from renal cell carcinoma remains unclear. To improve patient care, the authors sought to standardize practical management strategies. They performed an unstructured literature review and elaborated on the current management strategies through an international group of experts from different disciplines assembled via the network of the International Kidney Cancer Coalition. Experts from different disciplines were administered a survey to answer questions related to current challenges and unmet patient needs. On the basis of the integrated approach of literature review and survey study results, the authors built algorithms for the management of single and multiple brain metastases in patients with renal cell carcinoma. The literature review, consensus statements, and algorithms presented in this report can serve as a framework guiding treatment decisions for patients. CA Cancer J Clin. 2022;72:454‐489.

show abstract

c-Met expression in renal cell carcinoma with bone metastases

Cited by 14 publications

References 101 publications

Receptor tyrosine kinases: biological functions and anticancer targeted therapy

Receptor tyrosine kinases: biological functions and anticancer targeted therapy

Research Progress of Tumor Microenvironment Targeted Therapy for Clear Cell Renal Cell Carcinoma

An interdisciplinary consensus on the management of brain metastases in patients with renal cell carcinoma

Contact Info

Product

Resources

About